Sandoz takes Amgen to court again, challenging its patents on decades-old Enbrel
Sandoz has filed an antitrust lawsuit in federal court in Virginia claiming that Amgen has blocked competition to “unlawfully extend its monopoly” on Enbrel. It is the second time the generics and biosimilars specialist has challenged Enbrel's patents in federal court.
Sandoz has filed an antitrust lawsuit in federal court in Virginia claiming that Amgen has blocked competition to “unlawfully extend its monopoly” on Enbrel. It is the second time the generics and biosimilars specialist has challenged Enbrel's patents in federal court.
